144412-49-7
144412-49-7
Chemical Structure
Lamifiban
Synonym(s): Ro 44-9883
- CAS No.: 144412-49-7
- Formula:C24H28N4O6
- Molecular Weight:468.50
IUPAC Name: 2-((1-((4-carbamimidoylbenzoyl)-L-tyrosyl)piperidin-4-yl)oxy)acetic acid
InChIKey: FPKOGTAFKSLZLD-FQEVSTJZSA-N
SMILES: O=C(O)COC1CCN(C([C@@H](NC(C2=CC=C(C(N)=N)C=C2)=O)CC3=CC=C(O)C=C3)=O)CC1
Biological Activity: Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lamifiban | Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moliterno DJ, et al. Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study. J Thromb Thrombolysis. 1995;2(3):165-169. [Content Brief]
